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INTRODUCTION 
 
Hypertensive disorders of pregnancy complicates around 5-10% of all 
pregnancies 1. It is one of the common causes of maternal & perinatal 
morbidity and mortality.  
 
How pregnancy initiates the rise in blood pressure or aggravates 
hypertension still remains an enigma inspite of research for many decades 
and it still remains one among the most significant and unsolved problems 
in obstetrics. 
 
Studies state that abnormal placentation and endothelial dysfunction 
are the key factors in the development of preeclampsia. Several markers 
have been investigated as the predictors of pre-eclampsia. Lipid levels in 
early pregnancy can be a good predictor of development of pre-eclampsia in 
patients. Dyslipidemia in early pregnancy leads to more oxidative stress by 
the formation of lipid peroxides and reactive oxygen species, thus 
predisposing to the development of pre-eclampsia. 
 
According to WHO even in developed countries, preeclampsia 
accounts for 16% of maternal mortality (Khan & Colleagues 2009) 27. For 
every case of maternal death there are ten near miss cases. Such is the 
magnitude of this multi system disorder. 
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Berg & colleagues (2005) stated that around 50% of these 
preeclampsia related deaths are preventable6. 
 
Thus early identification of pregnancies at risk may enhance the 
development of new strategies for antenatal monitoring, to detect disease 
earlier and intervene appropriately to improve maternal and perinatal 
outcome. 
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REVIEW OF LITERATURE 
 
Hypertension is the most common medical problem encountered in 
pregnancy. It is the second most common cause of maternal mortality in 
India and a major cause of perinatal mortality and morbidity. Pre-eclampsia 
is not simply hypertension complicating pregnancy, but a protean disorder 
affecting virtually every system in the body. Hypertension is only one 
manifestation. 
 
According to the International Society for the study of Hypertension 
in pregnancy (ISSHP), hypertension is defined as a systolic blood pressure 
>140 mm Hg or a diastolic blood pressure >90 mm Hg. A rise in the systolic 
blood pressure of 30 mm Hg or a rise in the diastolic blood pressure of 
15mm Hg, at least 4 hours apart or a single diastolic blood pressure 
>110mm Hg is also considered as hypertension. 
 
In normal pregnancy, the diastolic blood pressure begins to fall in 
early pregnancy and continues to fall in the second trimester to reach a nadir 
at 22-24 weeks. 
 
Then it steadily rises to reach the prepregnant levels by term. This fall 
is due to the reduced vascular tone, which leads to peripheral vasodilatation. 
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CLASSIFICATION 
According to the latest classification by the working group of the 
National High Blood Pressure Education Programme (NHBPEP), 
hypertensive disorders of pregnancy is classified into five types: 
 
1. Gestational hypertension or pregnancy induced hypertension is 
non-proteinuric hypertension arising for the first time after 20 weeks 
of gestation. The blood pressure returns to normal within 12 weeks 
postpartum. It is a diagnosis of exclusion. 
 
2. Pre-eclampsia :  
New onset proteinuric hypertension after 20 weeks of 
gestation. 
 
3. Eclampsia :  
Eclampsia is defined as seizures that cannot be attributed to any 
other cause in a woman with pre-eclampsia. 
 
4. Chronic hypertension : 
Chronic hypertension is defined as hypertension antedating 
pregnancy or hypertension diagnosed before 20 weeks of pregnancy, 
but not attributable to gestational trophoblastic disease. Hypertension   
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first diagnosed after 20 weeks & persisting 12 weeks postpartum is 
also considered chronic hypertension. 
 
5. Superimposed Pre-eclampsia : 
This is defined as new onset proteinuria or a sudden increase in 
blood pressure or poteinuria in a woman with chronic hypertension. 
 
ETIOLOGY 
The exact etiology of preeclampsia is not known. But there are risk 
factors predisposing to development of pre-eclampsia. Genetic factors 
include family history of pre-eclampsia. 
 
Obstetric factors include primiparity, previous history of pre-
eclampsia, new paternity, multiple pregnancy, hydrops fetalis with large 
placenta, hydatidiform mole, triploidy. 
 
Medical factors include chronic hypertension, diabetes, renal disease, 
antiphospholipid antibody syndrome, inherited thrombophilias, connective 
tissue disorders, hyperhomocysteinemia. 
 
PATHOGENESIS 
The pathology of this multi system disorder should be considered as 
two staged process. 
1. Abnormal placentation 
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2. Maternal systemic reaction that produces clinical signs / symptoms 
that characterise this disorder. 
 
Abnormal Placentation :  
In normal pregnancy, the spiral arteries of the placenta are invaded by 
the cytotrophoblast and the elastic & muscular coats are replaced by 
fibrinoid .Early in second trimester, a second wave of cytotrophoblastic 
invasion occurs. This transforms the myometrial segments of the spiral 
arteries into wide mouthed vessels unresponsive to vasomotor stimuli. Thus, 
the blood supply is transformed from a high-resistance low-flow system to a 
low resistance high flow system in order to increase the uteroplacental flow 
to meet the demands of the fetus. 
 
In pre-eclampsia, the primary wave of trophoblastic invasion is partly 
impaired and the second wave fails to occur. This results in reduced 
uteroplacental blood flow, which worsens as the pregnancy advances. In 
addition, the arteries remain very sensitive to vasomotor stimuli. These 
changes are not specific to pre-eclampsia but also occurs in IUGR without 
pre-eclampsia. 
 
The myointimal cell proliferation, endothelial damage with medial 
necrosis forms the early pre-eclamptic changes. These findings with lipid 
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laden cells infiltration is termed as ‘atherosis’. A similar pathology is seen 
in atherosclerosis. 
 
Since abnormal lipid profiles are associated with atherosclerosis, the 
hypothesis of dyslipidemia for development of pre-eclampsia is biologically 
plausible. 
 
 
 
 
 
 
 
 
 
 
Fig 1: Abnormal Placentation in Preeclampsia 
 
Vasospasm & hypoxia - inducing systemic inflammatory response: 
These narrow spiral arteries impair perfusion leading to a hypoxic 
environment.  Hypoxia eventually leads to release of placental debris into 
maternal circulation inciting a systemic inflammatory response. 
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Dysregulation or loss of maternal immune tolerance to paternally 
derived placental debris leads to activation of leucocytes and release of 
cytokine resulting in endothelial injury. 
 
In pre-eclampsia, due to the endothelial dysfunction, there is a 
reduction in prostocyclin and nitric oxide, which are vasodilators and an 
increase in endothelin and thromboxane which are vasoconstrictors. Besides 
this, loss of vascular insensitivity to pressor agents results in vasospasm and 
thereby increases vascular resistance and blood pressure. 
 
Endothelial dysfunction leads to release of cytokines such as TNF- 
alpha and interleukins which may contribute to oxidative stress 
characterised by increased ROS(Reactive Oxygen Species) & free radicals 
that leads to formation of self propagating lipid peroxides. 
 
The increased levels of lipid peroxides and decreased antioxidant 
activity in pre-eclampsia have raised the possibility that markers of 
oxidative stress may predict pre-eclampsia. 
 
As blood lipids like triglycerides and free fatty acids and lipoprotein 
belong to the variety of pro-oxidants or potentiators of pro-oxidants, they 
can be used as markers of pre-eclampsia. 
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Endothelial dysfunction will lead to activation of platelets & 
coagulation system by the release of tissue factors from endothelium. This 
results in widespread DIC ranging from subclinical to frank DIC. 
 
PATHOPHYSIOLOGY 
Placenta :  
The typical vascular changes in pre-eclampsia is termed ‘atherosis’. 
This is characterised by fibrinoid necrosis, macrophages and mononuclear 
cell infiltration. 
 
Kidney : 
The main pathology in the kidney is glomerular endotheliosis, which 
narrows the lumen. This comprises swollen endothelial cells due to fibrin 
deposition. There is glomerular & tubular dysfunction. 
 
The main pathology is glomerular dysfunction, the manifestation of 
which is proteinuria. There is also reduction in glomerular filtration rate and 
creatinine clearance, which in severe cases leads to increase in the blood 
urea & serum creatinine.Acute renal failure can rarely supervene and is 
usually due to acute tubular necrosis which is reversible.  
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Tubular dysfunction is manifested by hyperuricemia. Hyperuricemia 
is also caused by the placental ischemia leading to increased trophoblastic 
turnover and increased production of purines. 
 
Liver : 
Periportal thrombosis and fibrin deposition, haemorrhages and 
necrosis are seen in the liver. There is an increase in the liver enzymes 
SGOT and SGPT and clinical jaundice can occur. The liver changes are 
responsible for the nausea and vomiting in severe cases. The small 
haemorrhages may coalesce to form a subcapsular hematoma, which may 
cause stretching of the Glison’s capsule and epigastric pain. This is a very 
serious sign and seen in impending eclampsia .These changes are 
responsible for HELLP Syndrome .An extremely rare but catatrophic 
complication is liver rupture. 
 
Brain: 
The main finding in the brain is cerebral vasospasm. Small cerebral 
haemorrhages, thrombosis and fibrinoid necrosis can occur especially in 
eclampsia and are secondary to endothelial dysfunction. Cerebral oedema is 
also usual in eclampsia. 
 
Massive cerebral haemorrhage is a rare complication of severe 
hypertension. Visual disturbances are common and usually due to edema of 
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the occipital lobe. Cortical blindness can occur due to occipital edema, 
which is usually temporary. 
 
Eyes:  
Localised retinal vasospasm is the commonest finding. Haemorrhages 
and papilloedema may be seen rarely seen in severe hypertension. Blindness 
could rarely due to retinal artery ischemia or infarction. 
 
COMPLICATIONS  
Pre-eclampsia can virtually affect any organ in the body. Hence 
complications can be expected in any organ in this multi-system disorder. 
Maternal complications include  
• Eclampsia 
• Cerebral hemorrhage 
• Cortical blindness 
• Pulmonary edema 
• ARDS(Adult Respiratory Distress syndrome) 
• HELLP syndrome  
• DIC and hemorrhage 
• Renal failure 
• hepatic rupture, 
• abruptio placenta & sudden postpartum collapse. 
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Fetal complications   
• Prematurity 
• IUGR 
• Intra uterine death. 
 
PREDICTORS OF PRE-ECLAMPSIA:  
As early detection of pregnancies at risk may lead to development of 
new strategies for antenatal monitoring and improve maternal and perinatal 
outcome, many markers have been proposed as predictors of pre-eclampsia. 
 
These are biological, biochemical, biophysical markers of impaired 
placental perfusion, vascular resistance, fetal- placental endocrine 
dysfunction, oxidant stress, endothelial dysfunction, activation of 
coagulation related to the pathophysiology of pre-eclampsia. 
 
But no single test is economical and sensitive. Some of them are: 
1) Mean arterial pressure (MAP) – in the second trimester 90mm Hg or 
more is a predictor of pre-eclampsia. 
2) Gant’s roll over test – The woman is turned from the left lateral to the 
supine position. If there is an increase in the diastolic blood pressure 
of 20mm Hg or more, the test is considered positive. 
3) Angiotensin Sensitivity test – is based on the fact that women 
destined to develop pre-eclampsia lose their refractoriness between 
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28-32 weeks of gestation. If a pressor response occurs with 
<8ng/kg/min of infused angiotensin, 90% are likely to develop pre-
eclampsia.But this pressor provocative test is invasive. 
4) Uterine artery Doppler – in the non-pregnant state there is decreased 
diastolic flow and notching of the uterine arteries. In normal 
pregnancy, due to the trophoblastic invasion, this notch disappears 
and the flow increases. If there is persistence of a diastolic notch in 
the uterine artery at 20-22 weeks of gestation, it indicates that the 
second wave of trophoblastic invasion has not occurred and is 
predictive of pre-eclampsia.  
The negative predictive value is better than the positive predictive 
value that is the disappearance of the notch is more likely to predict 
that the pregnancy is likely to normal. 
5) Pulse wave analysis:  similar to the uterine artery Doppler 
velocimetry, ‘stiffness’ in the finger arterial pulse acts a pre-
eclampsia predictor. 
6) Raised Uric acid – the placental ischemia leads to increased 
trophoblastic turnover and increases the production of purines. Uric 
acid being the metabolite of purine metabolism is increased and is 
one of the earliest laboratory manifestations of pre-eclampsia. 
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7) Raised serum beta hCG at 14-20 weeks of gestation –  Due to 
abnormal trophoblastic invasion – beta hCG is produced in increased 
amounts. This is also due to placental dysmaturity. The hypoxic 
trophoblast reacts to diminised oxygen by an oversecretory effect thus 
leading to increased beta hCG production. 
8) Tests relating to fetal-placental unit endocrine dysfunction are – alpha 
fetoprotein (AFP), estriol levels, Pregnancy associated Protein A 
(PAPP A), inhibin A levels, Activin A, Placental protein 13, 
corticotrophin releasing hormone. 
9) Platelet count, fms – like tyrosine kinase receptor-1(sFlt-1), endoglin 
plasminogen activitator inhibitor (PAI) , neurokinin B, p-selectin, 
decreased levels of pro-angiogenic factors that includes vascular 
endothelial growth factors(VEGF), placental growth factor(PlGF), 
endothelial adhesion molecules, C- reactive proteins – are all claimed 
as predictors of pre-eclampsia as they are markers of either 
endothelial dysfunction  or  oxidative stress. 
10) Free fetal DNA – due to ischemia in placentation – there is 
accelerated apoptosis of cytotrophoblast in pre-eclampsia. This leads 
to release of free - fetal DNA in to maternal circulation. 
11) Dyslipidemia as a predictor of pre-eclampsia – as blood lipids 
including triglycerides , free fatty acids and lipoproteins belongs to 
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the variety of pro-oxidants or potentiators of  pro-oxidants they can 
be used as markers to predict pre-eclampsia.  
 
The correlation between abnormal lipid profiles and development of pre-
eclampsia is proposed based on two hypotheses. 
a) Lipoproteins and lipids are potentiators of oxidative stress. Hence an 
abnormally elevated lipid levels leads to more oxidative stress 
resulting in endothelial dysfunction – which is the key step in the 
pathogenesis of this common disorder of pregnancy. 
b) The second mechanism is through the metabolic syndrome X (or) 
insulin resistance syndrome. Hyperinsulinemia & hyperuricemia is 
also present in pre-eclampsia. 
 
Hyperinsulinemia alters the function of lipoprotein lipase in the 
adipose tissue – an important post hepatic enzyme in the lipid metabolism. 
The altered lipoprotein lipase eventually leads to abnormally elevated levels 
of triglycerides and free fatty acids. Increased insulin levels also causes 
mobilisation of lipids from the visceral fats. It also enhances the production 
of Very Low Density Lipoprotein in the liver.  
 
This also explains that the genetic & environmental factors leading to 
metabolic X syndrome is also important in determining the occurrence of 
pre-eclampsia. 
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Lipid metabolism in normal pregnancy 
The concentrations of lipids, cholesterol, lipoproteins increases 
during pregnancy. Fat accumulation occurs primarily in the mid pregnancy. 
The total increase in fat is around 3.5kg, mainly central in its distribution in 
the abdomen, breasts, hips and thighs rather than in peripheries. This storage 
occurs to meet the increased demands of third trimester for transfer of 
essential fatty acids which is required by the fetus during its maximal 
growth.  
 
These changes are due to the effects of progesterone. Progesterone 
acts and alters the hypothalamic lipostat.  After delivery, the progesterone 
rests the lipostat to its previous non-pregnant state. Thus, the concentration 
of lipids decrease and lactation accelerates this decrease. 
 
The most important change in lipid profile during pregnancy is 
hyperlipidemia. There is a consistent increase in glycerides mainly 
triglycerides. The other components such as total cholesterol, Low Density 
Lipoprotein, High Density Lipoprotein, Very Low Density Lipoprotein is 
also increased during pregnancy. 
 
These are due to the effects of sex hormones especially estrogen & 
progesterone on the liver.  
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The lipolytic activity is also increased and the activity of lipoprotein 
lipase in decreased especially in adipose tissue. Although, there is a 
physiological hyperlipidemia in normal pregnancy, the rise is even higher in 
pregnancies complicated by pre-eclampsia and this occurs even earlier. 
 
Management: 
Mild preeclampsia: 
Patients with mild preeclampsia can be treated on an outpatient basis. 
Day care units are helpful. Whether admitted to hospital or not, monitoring 
of maternal and fetal condition is essential.  
 
Sedentary activity throughout the greater part of the day is 
recommended. There is no place for salt restriction, diuretics or sedatives. 
Diuretics will further reduce the uteroplacental flow and worsen the IUGR. 
The only indication for diuretics is pulmonary edema. 
 
Antihypertensives : 
The effectiveness of antihypertensives in mild preeclampsia is 
controversial. The main objective is to reduce the risk of severe 
hypertension and cerebral haemorrhage. Once the mean arterial pressure 
(MAP) is more than 150 mm Hg, there is loss of cerebral autoregulation and 
a high risk of cerebral haemorrhage. Antihypertensives may help in 
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prolongation of pregnancy, but it is important to remember that the disease 
process is not modified. Therefore, there is danger that they may mask the 
detection of severity. Overzealous correction of hypertension may lead to 
further reduction in uteroplacental flow and IUGR and hence best avoided. 
The commonly used first line drugs are alpha methyl dopa, nifedipine and 
labetolol. Labetolol should be avoided in women with known asthma. 
 
Monitoring: 
Maternal  
• Blood pressure and urine albumin daily. 
• Urine output daily 
• Alternate day weight 
• Watch for imminent symptoms 
• Twice weekly peripheral smear,platelet count, coagulation 
profile,uric acid,renal and liver function tests. 
 
Fetal: 
• Daily fetal movement count 
• Ultrasound to assess fetal growth and well being 
• NST and amniotic fluid volume assessment 
• Doppler velocimetry in IUGR 
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The frequency of monitoring has to be individualised depending upon 
the severity and presence of IUGR. 
 
Delivery 
Delivery is the only definitive treatment for preeclampsia and usually 
labour is induced at 38 weeks. Early termination may be needed if there is 
progression to severe preeclampsia or eclampsia with worsening of either 
the maternal or the fetal condition. Antenatal corticosteroids to accelerate 
lung maturity should be considered if preterm. If there are no obstetric 
indications for caesarean section labour can be induced. If the cervix is 
favourable, ARM and oxytocin infusion is used for induction. If the cervix 
is unfavourable, PGE2 gel can be used to ripen cervix .Continuous CTG 
monitoring is ideal during labour. AMTSL should be followed. 
 
SEVERE PREECLAMPSIA  
In severe preeclampsia, there is deterioration of either the maternal 
and fetal condition or both and again the only definitive treatment is 
delivery. After 34 weeks, severe preeclampsia is best treated by termination 
especially if there is worsening of biochemical parameters. Severe 
preeclampsia developing before 24 weeks is probably best managed by 
termination of pregnancy. In cases before 34 weeks if the initial condition 
stabilises there may be a place for expectant management. 
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EXPECTANT MANAGEMENT  
The aim of the expectant management is to protect the mother and the 
fetus from the consequences of the disease and at the same time, prolong 
pregnancy if possible to avoid the dangers of prematurity to the fetus. At 
any time when there is a worsening in the condition, expectant management 
is abandoned and immediate termination decided. 
 
Antihypertensives are definitely indicated to prevent cerebral 
haemorrhage. The main danger is that they may give a false sense of 
security by masking hypertension. 
 
Close monitoring of maternal and fetal condition is performed as in 
mild preeclampsia but much more frequently. Poor oxygen saturation can 
occur in pulmonary edema and so measurement of oxygen saturation using 
pulse oximetry is indicated in such cases. Antenatal corticosteroids to 
accelerate lung maturity. 
 
INDICATIONS FOR IMMEDIATE TERMINATION OF 
PREGNANCY 
• Uncontrolled hypertension 
• Imminent eclampsia or eclampsia 
• Abnormal renal or liver function tests or coagulopathy 
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• HELLP syndrome 
• Fetal distress 
• Severe IUGR 
• Abruption 
• Pulmonary edema 
 
INTRAPARTUM MANAGEMENT 
Control of blood pressure: 
The diastolic blood pressure should not be allowed to cross 110 mm 
Hg. Labetolol, hydralazine and nife dipine can be used. Whatever the drug 
used, a rapid fall in blood pressure should be avoided, as it may be 
deleterious to the fetus. Hence close monitoring of the blood pressure is 
essential. 
 
Prophylactic magnesium sulphate may be given during labour to 
prevent eclampsia. 
 
Fluid Management : 
Preeclamptic patients have increased extracellular fluid although 
there is contracted intravascular volume. Excessive parenteral fluids can 
lead to fluid overload and pulmonary edema, which may be fatal. If there is 
coagulopathy or HELLP syndrome, blood and blood products like fresh 
frozen plasma and platelet concentrate may have to be given.  
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INDICATIONS FOR CESEAREAN SECTION  
• Associated obstetric indications 
• Failed induction 
• Rapid worsening of maternal condition and delivery not imminent 
• Fetal distress or severe IUGR 
 
Lewis & Steiner et al (1996) – did a study on several ways by which 
the vascular function is compromised by elevated triglycerides. 
 
They stated that the lipoprotein that is rich in triglycerides have 
tendency towards pro-thrombotic activity, thus having a role in pathology of 
pre-eclampsia. 28 
 
Plotnick et al and Vogel et al studied the role of lipoprotein that is 
rich in triglycerides in inhibiting the vasodilation that is endothelium 
dependent. Triglycerides stimulates NADPH oxidase especially leucocytes 
NADPH oxidase, and increases peroxidation susceptible LDL particles.   
 
Both of these leads to increased production of Reactive Oxygen 
Species. Reactive Oxygen Species in turn can either destroy nitric oxide or 
inhibit nitric oxide synthase leading to decreased bio availability of nitric 
oxide, a prime factor in endothelium dependant vasodilatation, hence 
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explaining the role of triglyceride rich lipoprotein in pathogenesis of  pre-
eclampsia28. 
 
R.K. Vidyabati, Hijam Davina et al studied the predictive role of 
abnormal lipid profile in early pregnancy in development of preeclampsia. 
This study included 164 pregnant women between 14 to 20 weeks of 
gestation and their lipid levels checked. 29 cases developed PIH, while 135 
cases remained normotensive2.   
 
Concentration of total cholesterol & very Low Density Lipoprotein in 
women who subsequently developed PIH were substantially higher than that 
of normotensive pregnant women (p <0.027). 
 
In this study for each unit increase in total cholesterol there was a 
12.6% increase in the risk of occurrence of preeclampsia. And for a unit 
increase in TG & LDL there was a 0.3%, 7.4% increase in the risk of 
developing PIH. Thus, this study has shown that the dyslipidemia as a good 
non-invasive predictor of preeclampsia.  
 
JG Ray, P Diamond b (2006) studied the risk of preeclampsia in the 
presence of maternal hypertriglyceridemia. Two investigators searched 
studies from 1980 to 2004 related to dyslipidemia and preeclampsia. 
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Out of the 22 total studies included; 3 were cohort studies and the rest 
were case control studies. In 14 studies, there was a higher mean 
triglyceride concentration among preeclampsia cases than among 
normotensive controls. 
 
When potential confounders were adjusted in four of the studies, 
there was a fourfold higher risk of preeclampsia. 
 
The authors concluded that there exists a consistent positive 
association between elevated maternal triglycerides and risk of 
preeclampsia. They also concluded that since hypertriglyceridemia is one of 
the features of insulin resistance syndrome, further additional studies are 
required to find out whether interventions such as lifestyle modification 
leading to decreased BMI in prepregnancy can lower the risk of pre-
eclampsia.3 
 
Lorentzen B, Henriksen T - (1998) did a study to show the role of 
abnormal lipid profile in pathology of preeclampsia. They suggested that 
preeclampsia has a similar pathology as that of atherosclerosis. In both these 
disorders endothelial dysfunction is induced by hyperlipidemia.  
Hyperlipidemia induces endothelial injury by promoting oxidative stress in 
the arterial wall. 
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According to them, the effects of placentally derived endothelial 
disturbing factors may be enhanced because of hyperlipidemia mediated 
activation or sensitization of the endothelial cells4 
 
Anceschi M M coata G et al in 1992 studied the composition of RBC 
membrane in preeclampsia. The altered composition acts as an indirect 
evidence for altered lipid profile. 
 
This study included 30 women with preeclampsia and 26 controls 
matched for gestational age who were normotensive pregnant women &10 
more normotensive nonpregnant nulliparous women. The cholesterol/ 
phospholipid ratio was significantly higher in women with preeclampsia 
than pregnant women with normal BP. This represents one factor involved 
in pathogenesis of preeclampsia and a possible predictive factor for the 
disease5. 
 
Van Den Elzen HJ, Wladimroff JW, Cohen Overbeek TE studied the 
relationship between serum lipid levels in early pregnancy and the 
occurrence of preeclampsia. 
 
This prospective cohort study included three ninety three pregnant 
patients. The study told that first trimester serum total cholesterol if higher 
was significantly associated with the risk of preeclampsia. 
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The adjusted relative risk exceeds 5 for women with serum total 
cholesterol Levels more than 6 mmol per  litre12. 
 
Arpita Basu, Peter Alaupovic  et al studied the link between maternal  
abnormal lipid profile and preeclampsia in women with type1 diabetes. 
 
This study included 118 Type1 diabetes pregnant patients. Serum 
lipid profiles, sub classes of lipoproteins, serum apolipoproteins were 
measured. Early in pregnancy increased cholesterol rich lipoproteins were 
associated with subsequent preeclampsia12. 
 
Lorentzen B Drevon CA et al studied the composition of esterified 
free fatty acids in the sera of women with preeclampsia and normal 
pregnancy. The fasting blood samples from 510 healthy nullipara at 17-19 
weeks of gestation were taken and analysed. Among the circulating free 
fatty acids the levels of palmitic, oleic and linoleic acids were significantly 
higher early in pregnancy in women who later developed proteinuric 
hypertension. 
 
The same free fatty acids were also increased in women with 
preeclampsia. Thus the study concluded that the level and the composition 
of circulating lipids were already altered 10-20 weeks before the clinical 
diagnosis of preeclampsia 7 
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Clausen T, Djurovics , Henriksen TE yet all 2001 investigated 
whether increased triglyceride is associated with early or late onset 
preeclampsia. It was a prospective Cohort study. Nested case control study 
design was also included.  
 
Multiple logistic regressions were used to analyse cohort data and 
conditional logistic regression for case control data. This study was done on 
2157 pregnant volunteers 18 women were diagnosed with early onset 
preeclampsia. Late onset preeclampsia was diagnosed in 53 women. 
 
They concluded that increased triglyceride in early weeks of 
pregnancy strongly related with the occurrence of early onset preeclampsia. 
Late onset preeclampsia did not have any association. 
 
Thus this study supported the hypotheses that there exists pathogenic 
differences between early and late onset preeclampsia 11. 
 
Satar N, Bendomir A et al studied the relationship of concentration of 
lipoprotein subfractions in normal pregnant patient and compared it with 
preeclamptic patients. 
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This study concluded that there is significant rise of triglyceride rich 
glycoprotein in patients with proteinuric hypertension compared with 
normal pregnant patients. 
 
They suggested that abnormal lipid profile will increase oxidative 
stress through small dense low density lipoprotein formation. Thus 
eventually leading to endothelial dysfunction. This study also supports the 
view of pathogenic similarity between atherosclerosis and preeclampsia14. 
 
Barden AE, Beilin LJ et al(1999) studied the various factors in non-
pregnant and pregnant  that predisposes to pre-eclampsia. It was a 
retrospective study that included 62 pre-eclamptic women & 84 normal 
pregnant women. 
 
Factors such as anthropometry, blood pressure & various laboratory 
parameters were analysed. In this study, irrespective of the parity, patients 
with hypertension had abnormally increased BMI and lipid concentration 
during pre-conceptional, natal and postnatal periods. 
 
The study concluded that abnormal lipid concentrations, increased 
BMI in the non-pregnant state symbolises insulin resistance syndrome. 
These factors sensitise the endothelium and predisposes to development of 
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pre-eclampsia. The same explanation holds good for genetic predisposition 
of pre-eclampsia.15. 
 
Barden A (2006) studied the various maternal constitutional 
parameters leading to the risk of developing Preeclampsia. He concluded 
that already existing increased blood pressure, altered glucose tolerance, 
increased BMI,& dyslipidemia greatly raise the risk of development of 
preeclampsia. This study also stresses the role of insulin resistance as a risk 
factor of developing preeclampsia16 
 
Daniel et al (2004) studied the role of abnormal lipid profile in early 
gestation and the occurrence of preeclampsia later in pregnancy. This 
prospective study included 567 women out of which 57 developed 
preeclampsia.  
 
The procedure used for calculation is logistic regression. The risk of 
proteinuric hypertension increased linearly with increasing low density 
lipoprotein concentrations. Thus they concluded that abnormally raised lipid 
levels in early gestation can act as a marker and   a predictor of 
preeclampsia17. 
 
Wolf  M, Kettyl et al (2001)  studied  the relationship of obesity with 
inflammation in the development of preeclampsia18.  
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They showed that the levels of inflammatory mediators are present in 
increased levels in the serum of patients in early gestation who developed 
preeclampsia later in gestation. 
 
They stated that obesity through inflammation makes the pregnant 
women more prone for preeclampsia if she is obese.18 
 
Thadhani et al (1999) studied the role of prepregnant obesity and 
abnormal lipid profile in the development of hypertensive disorders of 
pregnancy. The study included 15262 women. 
 
They concluded that preconceptional obesity and dyslipidemia may 
be used as markers of development of preeclampsia during pregnancy. 
 
They found no relationship between dyslipidemia and the occurrence 
of gestational hypertension. They hypothesised that dyslipidemia promotes 
the formation of lipid peroxides and reactive oxygen species and makes an 
imbalance of vasoactive mediators leading to endothelial dysfunction and 
vasospasm – a protean event in the pathogenesis of preeclampsia19. 
 
Hubel CA, Lyall et al did a nested case control study in 1998 
comparing the levels of SLDL and VCAM-1 in  preeclamptic  women with 
gestationally matched normal pregnant women without any complications. 
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The size and density distribution of LDL is influenced by the serum levels 
of TGL. These small LDL are promoters of endothelial dysfunction. 
 
Hypertriglyceridemia was observed in preeclamptic patients and the 
Low density Lipoprotein peak particle diameter had an indirect association 
with risk of preeclampsia.  
 
They concluded that the rise in concentration of small and denser 
LDL in directly related to the development of preeclampsia. The other 
marker of endothelial involvement that was tested was VCAM-1 which was 
influenced by the amount of lipoproteins and not the particle size20. 
 
Ware – Jauregui et al (1999) conducted a case control study that 
included 125 preeclamptic women as cases and 179 pregnant patients 
without any complications as controls. 
 
The levels of triglycerides were on the higher side in case of patients 
with proteinuric hypertension. For each quartile increase in the levels of 
triglycerides there was a consistent rise in the development of preeclampsia. 
 
They concluded that the levels of high density lipoprotein had an 
inverse relationship with occurrence of preeclampsia21. 
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Vanderjagt DJ, Patel RJ et al (2004) studied the role of homocysteine 
levels and the development of preeclampsia. They also studied the 
relationship between homocysteine levels and HDL levels. 
 
They concluded that hyperhomocysteinemia is directly related to 
preeclampsia and HDL levels are inversely related to preeclamptic risk22. 
 
O ‘Brien et al (2003) investigated the role of prepregnant body weight 
in the development of preeclampsia. They concluded that increased BMI 
increases the risk of preeclampsia.  
 
They also highlighted the increasing incidence of preeclampsia in 
developed countries, where there is an increasing tendency towards obesity, 
thus insisting on weight reduction during the pre-pregnant state23. 
 
Gratocos  E, casal E et al(2003) did a  case control study in 70 
patients. LDL oxidation susceptibility and lipids were measured. They 
found that the mean lipid levels were greatly increased in preeclamptic 
women when compared with normotensive controls. 
 
The study also showed that the LDL in Preeclampsia patient were 
more prone to oxidation with a p value <0.0124. 
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Wakatsuki A et al (1996) did a comprehensive study of antioxidant 
status and oxidative stress in preeclampsia and compared it with normal 
pregnancy.  
 
This study also supported that the HDL levels were low in patzents 
with hypertension 25. 
 
Mikhail et al studied the levels of TGL in preecalmptic women and 
concluded that there exists a positive correlation with severity of 
preeclampsia. 
 
Bodnar et al (2005)26 did a study to find out the role of pre-pregnancy 
obesity in the development of pre-eclampsia  in a dose dependant relation.  
This was a prospective cohort study that included 1179 women in their first 
pregnancy at 16 weeks of gestation. 
 
They concluded that the risk of pre-eclampsia rises with increasing 
BMI and the risk decreases with decrease in BMI. 
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AIM OF THE STUDY 
 
To study whether abnormal lipid profile in the second trimester of 
pregnancy can be a predictor of pre-eclampsia. 
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MATERIALS AND METHODS 
 
STUDY DESIGN 
Prospective Cohort Study. 
 
STUDY PERIOD  
Between Oct 2010 to Mar 2012 
 
PLACE OF STUDY 
Antenatal clinic, Department of Obstetrics & Gynaecology Kilpauk 
Medical College and Hospital. 
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SAMPLE SIZE 
 
The sample size was calculated using the formula, 
 
 
Z - Constant (1.96). 
P - Prevalence (0.05). 
d - Desired precision (0.05). 
 
 
  
= 125 
My sample size is 129. 
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INCLUSION CRITERIA 
1) Pregnant women with singleton pregnancy 
2) With LMP & USG confirmed pregnancy between 17-19weeks of 
gestation. 
 
EXCLUSION CRITERIA 
1) Diabetes mellitus 
2) Chronic hypertension 
3) Renal disorder 
4) Hypothyroidism 
5) Family/personal history of  dyslipidemia 
6) On Any medications except for vitamins & minerals 
7) Ultra sound proved congenital anamolies 
8) PCOS 
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METHODOLOGY 
 
A total of 129 antenatal patients who attended the antenatal clinic of 
the Department of Obstetrics & Gyncecology, Govt Kilpauk Medical 
College, were selected based on the inclusion & exclusion criteria after 
obtaining their informed consent.  
 
All selected women   were subjected to a detailed history taking 
comprising of age, parity, prepregnant body weight, medication history, 
family history, medical history, detailed obstetric history including previous 
history of preeclampsia. Then they were subjected to clinical examination 
and routine laboratory investigations were carried out on the first day. 
 
Fasting blood samples (4ml) were collected from these patients on the 
next day and subjected to lipid profile analysis. Total Cholesterol, HDL, 
TGL levels were estimated and the levels of LDL and VLDL were 
calculated indirectly. 
 
These patients were regularly followed up in the antenatal op till their 
delivery once in every two weeks and a thorough clinical examination was 
carried with special focus on blood pressure and urine albumin. All the 
details were entered. 
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Definitions used for diagnosis of preeclampsia was according to the 
International Society for the study of Hypertension in pregnancy (ISSHP). 
Hypertension is defined as a systolic blood pressure >140 mm Hg or a 
diastolic blood pressure  >90 mm Hg. 
 
A rise in the systolic blood pressure of 30 mm Hg or a rise in the 
diastolic blood pressure of 15mm Hg, at least 4 hours apart or a single 
diastolic blood pressure >110mm Hg is also considered as hypertension 
with proteinuria of at least ‘1+’ or 1 g/L on dipstick. 
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RESULTS OF THE STUDY 
 
• The patients who developed pre-eclampsia were grouped as 
preeclampsia cohort. 
• And the rest of the patients who remained normotensive till delivery 
were grouped as normal cohort. 
 
The factors taken for analysis were age distribution, obstetric score, 
Body Mass Index, history of preeclampsia in previous pregnancy, and the 
components of lipid profile. Mean + SD of all variables of interest were 
determined for preeclampsia cohort and for normal cohort separately and 
difference was tested by t test. 
 
The predictive values of the individual components of lipid profile 
were analysed using ROC curve.  
 
Logistic regression model was used to estimate the causal effect of 
each predisposing factor on outcome and to find out the most effective 
predictor. 
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TABLE – 1 : AGE DISTRIBUTION OF PATIENTS IN THE STUDY 
 
AGE IN 
YEARS 
PREECLAMPSIA 
COHORT 
NORMAL COHORT 
NO. OF CASES % NO. OF CASES % 
<24 YEARS 9 52.9 48 42.9 
25-29 YEARS 7 41.2 51 45.5 
>30 YEARS 1 5.9 13 11.6 
TOTAL 17 100 112 100 
 
Chi square test    0.848        
p=0.654 
 
52.9% of the patients in preeclampsia cohort and 42.9% of the 
patients in the normal cohort were in the age group of < 24 years.  
 
41.2% of the patients in preeclampsia cohort and 45.5% of the 
patients in the normal cohort were in the age group of 25-29 years. 
 
5.9% of the patients in preeclampsia cohort and 11.6% of the patients 
in the normal cohort were in the age group of >30 years. 
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FIGURE 2 : AGE DISTRIBUTION OF PATIENTS IN THE STUDY 
 
INFERENCE  
There is no statistical significance between the preeclampsia cohort & 
normal cohort with respect to age distribution. 
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TABLE – 2 : OBSTETRIC SCORE OF PATIENTS IN THE STUDY 
 
GRAVIDA 
PREECLAMPSIA 
COHORT 
NORMAL COHORT 
NO. OF CASES % NO. OF CASES % 
PRIMI 10 58.8 72 64.3 
GRAVIDA2 7 41.2 35 31.3 
GRAVIDA3 0 0 5 4.5 
TOTAL 17 100 112 100 
 
Chi square test   = 1.275     
p=0.529 
 
58.8% of the patients in preeclampsia cohort and 64.3% of the 
patients in the normal cohort were primigravida. 
 
No patients in preeclampsia cohort was gravida 3, while 4.5% of 
patients in normal cohort were gravid 3. 
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FIGURE 3 : OBSTETRIC SCORE OF PATIENTS IN THE STUDY 
 
 
 
 
 
 
 
 
 
 
INFERENCE 
There is no statistical significance between the preeclampsia cohort & 
normal cohort with respect to obstetric score. 
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TABLE-3 : SOCIO-ECONOMIC CLASSIFICATION OF PATIENTS 
IN THE STUDY 
 
SOCIO-
ECONOMIC 
CLASSIFICATION 
PREECLAMPSIA 
COHORT 
NORMAL COHORT 
NO. OF CASES % NO. OF CASES % 
UPPER MIDDLE 1 5.9 16 14.3 
LOWER MIDDLE 10 58.8 62 55.4 
UPPER LOWER 6 35.3 34 30.4 
TOTAL 17 100 112 100 
 
Chi square test     =     0.939    
p=0.625 
 
58.8% of the patients in preeclampsia cohort and 55.4% of the 
patients in the normal cohort belongs to lower middle group of socio 
economic classification according to Kuppuswamy classification. 
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FIGURE 4 : SOCIO-ECONOMIC CLASSIFICATION OF PATIENTS 
IN THE STUDY 
 
 
INFERENCE 
There is no statistical significance between the preeclampsia cohort & 
normal cohort with respect to socio economic classification. 
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TABLE – 4 : HISTORY OF PREECLAMPSIA IN PREVIOUS 
PREGNANCY IN PATIENTS IN THE  STUDY 
 
 
PREECLAMPSIA 
COHORT 
NORMAL COHORT 
NO. OF 
CASES 
% 
NO. OF 
CASES 
% 
With prev H/O 
preeclampsia 
3 17.6 3 2.7 
Without prev H/O 
preeclampsia 
14 82.4 109 97.3 
TOTAL 17 100 112 100 
 
Chi square test = 7.457    
p = 0.06 
 
17.6% of the patients in preeclampsia cohort and 2.7% of the patients 
in the normal cohort has previous history of preeclampsia . 
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FIGURE 5 : HISTORY OF PREECLAMPSIA IN PREVIOUS 
PREGNANCY IN PATIENTS IN THE  STUDY 
 
  
INFERENCE 
The p value is 0.06 which shows that there exists a statistical 
significance between the two groups with respect to previous history of 
preeclampsia.  
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TABLE 5 : COMPARISON OF PRE-PREGNANT 
BMI BETWEEN PREECLAMPTIC & NORMAL COHORT 
 
 
NO. OF 
CASES 
MEAN 
BMI 
STANDARD 
DEVIATION 
STANDARD 
ERROR OF 
MEAN 
Preeclampsia 
cohort 
17 27.32 3.65 0.88 
Normal cohort 112 23.08 1.88 0.17 
 
p = 0.00   which is < 0.01 therefore significant. 
 
The Mean BMI of Preeclampsia cohort is 27.32kg/m2.  
 
The Mean BMI of Normal cohort is 23.08kg/m2.  
 
 The Mean BMI of Preeclampsia cohort is 4.24kg/m2 higher than the 
Normal cohort. 
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FIGURE 6: COMPARISON OF PRE-PREGNANT BMI BETWEEN 
PREECLAMPTIC & NORMAL COHORT 
 
 
INFERENCE:  
It is clear from the above table that the patients who developed 
preeclampsia had higher Body Mass Index during their prepregnant state 
than the nomotensive patients. The difference is statistically significant. 
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TABLE 6 : COMPARISON OF TOTAL CHOLESTEROL BETWEEN 
PREECLAMPTIC & NORMAL COHORT 
 
 
NO. OF 
CASES 
MEAN 
(mg%) 
STANDARD 
DEVIATION 
STANDARD 
ERROR OF 
MEAN 
Preeclampsia 
cohort 
17 248.24 46.63 11.31 
Normal 
cohort 
112 176.10 28.02 2.64 
 
p = 0.00   which is < 0.01 therefore significant. 
 
The Mean total Cholesterol of Preeclampsia cohort is 248.24mg%.  
 
The Mean total Cholesterol of Normal cohort is 176.10mg%.  
 
The Mean total Cholesterol of Preeclampsia cohort is 72.14mg% 
higher than the Normal cohort. 
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FIGURE 7 : COMPARISON OF TOTAL CHOLESTEROL 
BETWEEN PREECLAMPTIC & NORMAL COHORT 
 
 
 
INFERENCE 
The mean total cholesterol levels were higher in patients who 
developed preeclampsia. 
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TABLE 7 : COMPARISON OF HDL LEVELS BETWEEN 
PREECLAMPTIC & NORMAL COHORT 
 
NO. OF 
CASES 
MEAN 
(mg%) 
STANDARD 
DEVIATION 
STANDARD 
ERROR OF MEAN 
Preeclampsia 
cohort 
17 47.49 4.40 1.067 
Normal 
cohort 
112 52.11 8.918 0.843 
     
p = 0.02  significant. 
FIGURE 8 :COMPARISON OF HDL LEVELS BETWEEN 
PREECLAMPTIC & NORMAL COHORT 
 
 
INFERENCE  
The mean HDL levels were lower in patients who developed 
preeclampsia. 
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TABLE 8 : COMPARISON OF TGL LEVELS BETWEEN 
PREECLAMPTIC & NORMAL COHORT 
 
NO. OF 
CASES 
MEAN 
(mg%) 
STANDARD 
DEVIATION 
STANDARD 
ERROR OF MEAN 
Preeclampsia 
cohort 
17 311.95 82.334 19.96 
Normal 
cohort 
112 156.78 48.830 4.61 
 
p = 0.00   which is < 0.01 therefore significant.  
FIGURE 9 : COMPARISON OF TGL LEVELS BETWEEN 
PREECLAMPTIC & NORMAL COHORT 
 
 
INFERENCE  
The mean TGL levels were higher in patients who developed 
preeclampsia. 
 63 
TABLE 9 : COMPARISON OF LDL  LEVELS BETWEEN 
PREECLAMPTIC & NORMAL COHORT 
 
NO. OF 
CASES 
MEAN 
(mg%) 
STANDARD 
DEVIATION 
STANDARD ERROR 
OF MEAN 
Preeclampsia 
cohort 
17 138.43 38.92 9.44 
Normal 
cohort 
112 92.7 23.5 2.22 
 
p = 0.00   which is < 0.01 therefore significant.  
FIGURE 10 : COMPARISON OF LDL  LEVELS BETWEEN 
PREECLAMPTIC & NORMAL COHORT 
 
INFERENCE  
The mean LDL levels were higher in patients who developed 
preeclampsia. 
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TABLE 10 : COMPARISON OF VLDL LEVELS BETWEEN 
PREECLAMPTIC & NORMAL COHORT  
 NO. OF 
CASES 
MEAN 
(mg%) 
STANDARD 
DEVIATION 
STANDARD 
ERROR OF MEAN 
Preeclampsia 
cohort 
17 62.38 16.45 3.99 
Normal 
cohort 
112 31.3 9.74 0.92 
 
p = 0.00   which is < 0.01 therefore significant.  
FIGURE 11 : COMPARISON OF VLDL LEVELS BETWEEN 
PREECLAMPTIC & NORMAL COHORT 
 
 
INFERENCE  
The mean VLDL levels were higher in patients who developed 
preeclampsia. 
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TABLE 11 : MEAN VALUES OF BMI & TGL 
 
TABLE 12 : CORRELATION BETWEEN BMI AND TGL LEVELS 
 
 BMI &  
TGL 
Pearson Correlation .517 
Sig. (2-tailed) .000 
 
When the correlation co-efficient value is between 0 .5 to 1.0 it means 
there is high correlation .The Pearson correlation coefficient for BMI & 
TGL is 0.517 which means there exists a high positive correlation between 
BMI & TGL. 
 
 
 
 Mean Std. Deviation N 
BMI 23.6436 2.61297 129 
TGL 177.22 75.442 129 
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TABLE 13 : MEAN VALUES OF BMI & TOTAL CHOLESTROL 
 
 
 
 
 
The p value is 0.000 which means it is statistically significant. 
 
TABLE 14 : CORRELATION BETWEEN BMI AND TOTAL 
CHOLESTROL VALUES 
 
 
 
 
 The p value is 0.000 which means it is statistically significant. 
 
 The pearson correlation coefficient for BMI & TCHO is 0.382 which 
means there exists a positive correlation between BMI & TGL, but since the 
co-efficient value is 0.382 , it is of medium coorelation. 
 
 
 
 Mean Std. Deviation N 
BMI 23.6436 2.61297 129 
Total CHO 185.61 39.406 129 
 BMI & TCHO 
Pearson Correlation .382 
Sig. (2-tailed) .000 
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All univariate analysis were done. The following variables were statistically 
significant. 
1. Previous history of preeclampsia 
2. Pre-pregnant Body Mass Index 
3. Total Cholesterol Levels 
4. HDL levels 
5. TGL levels 
6. VLDL levels 
7. LDL levels 
 
The above variables were put in to the Binary Logistic Regression 
Model taking development of preeclampsia as a dependent variable. 
 
The two most statistically significant variables were  
1. TGL levels 
2. HDL levels 
 
The outputs are 
TABLE 15 : STATISTICAL SIGNIFICANCE OF HDL & TGL 
 
Variable Name Chi Square (Wald stat) p 
HDL 6.951 0.008 
TGL 21.557 0.000 
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CLASSIFICATION TABLE 
 
OVERALL PERCENTAGE CORRECTNESS = 96.1 % 
 
 
 
 
 
 OUTCOME OF THE STUDY 
 
PATIENTS WHO 
REMAINED 
NORMOTENSIVE 
PATIENTS WHO 
DEVELOPED 
PREECLAMPSIA 
PERCENTAGE 
CORRECTNESS 
MODEL 
PREDICTED 
NORMAL 
PATIENT 
110 2 98.2 
MODEL 
PREDICTED 
PRECLAMPSIA 
3 14 82.4 
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Receiver Operating Characteristic (ROC) Curve 
This curve is used for clinical prediction rules. The accuracy of the 
test is determined from are under the curve. 
 
If area under the curve is 0.90-1  then the accuracy is excellent , and 
if it is 0.80-0.90 then the accuracy is good . 
 
Testing BMI as a predictor of preeclampsia  
 
ROC curve for BMI 
 
Area under the ROC curve for BMI is 0.828 
 
BMI 
0 20 40 60 80 100
0
20
40
60
80
100
100-Specificity
Sensitivity
 Sensitivity: 58.8
 Specificity: 99.1
 Criterion : >27.0062
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Testing Total Cholesterol as  a  predictor,  
 
The ROC curve for total Cholesterol 
Total CHO
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Area under the ROC curve for Total CHO is 0.91 
Sensitivity – 94.12 % 
Specificity – 82.14% 
Criterion  >200 mg % 
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Testing  HDL as  a  predictor,  
 
The ROC curve for HDL 
HDL
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 Sensitivity: 76.5
 Specificity: 67.9
 Criterion : <=48.1
 
Area under the ROC curve for HDL is 0.68 
Sensitivity – 76.5% 
Specificity – 67.9% 
Criterion  <48.1mg % 
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Testing  LDL as  a  predictor ,  
 
The ROC curve for LDL 
LDL
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 Sensitivity: 64.7
 Specificity: 93.7
 Criterion : >119.6
 
Area under the ROC curve for LDL is 0.83 
Sensitivity – 64.7% 
Specificity 93.7% 
Criterion  >119.6mg % 
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Testing  VLDL as  a  predictor ,  
 
The ROC curve for VLDL 
VLDL
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 Sensitivity: 88.2
 Specificity: 97.3
 Criterion : >48
 
Area under the ROC curve for  VLDL is 0.91 
Sensitivity – 88.2% 
Specificity – 97.3% 
Criterion  >48mg % 
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Testing  TGL as  a  predictor ,  
 
The ROC curve for TGL 
TGL
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 Sensitivity: 88.2
 Specificity: 97.3
 Criterion : >240
 
Area under the ROC curve for TGL is 0.91 
Sensitivity – 88.2% 
Specificity – 97.3%      
Criterion  >240mg % 
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SUMMARY 
 
There is no statistical significance between the preeclampsia cohort & 
normal cohort with respect to age distribution. 52.9% of the patients in 
preeclampsia cohort and 42.9% of the patients in the normal cohort were in 
the age group of < 24 years .41.2% of the patients in preeclampsia cohort 
and 45.5% of the patients in the normal cohort were in the age group of 25-
29 years . 5.9% of the patients in preeclampsia cohort and 11.6% of the 
patients in the normal cohort were in the age group of >30 years. 
 
• 58.8%  of the patients in preeclampsia cohort and 64.3% of the 
patients in the normal cohort were primigravida. 
• 58.8%  of the patients in preeclampsia cohort and 55.4% of the 
patients in the normal cohort  belongs to lower middle group of socio 
economic classification according to kuppuswamy classification. 
• 17.6%  of the patients in preeclampsia cohort and 2.7%  of the 
patients in the normal cohort  has previous history of preeclampsia . 
• The Mean BMI of preeclampsia cohort was 27.32 while that of the 
normal cohort was 23.08.  This clearly shows that the preeclampsia 
cohort had higher BMI than their normal counterparts. 
• The mean total cholesterol levels were higher in patients who 
developed preeclampsia. 
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• The mean HDL levels were lower in patients who developed 
preeclampsia. 
• The mean TGL levels were higher in patients who developed 
preeclampsia. 
• The mean LDL levels were higher in patients who developed 
preeclampsia. 
• The mean VLDL levels were higher in patients who developed 
preeclampsia. 
• Area under the ROC curve for BMI is 0.828 
• Testing Total Cholesterol as  a  predictor, the  Sensitivity – 94.12 
%,Specificity – 82.14% 
• Area under the ROC curve for TGL is 0.91 
• Area under the ROC curve for  VLDL is 0.91 with Sensitivity – 
88.2% & Specificity – 97.3% 
• Area under the ROC curve for HDL is 0.68 
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DISCUSSION 
 
Our study included 129 pregnant women; recruited from patients 
attending antenatal OP department.17 patients developed preeclampsia and 
were grouped as the preeclampsia cohort and the remaining 112 pregnant 
women who were normal were taken as controls. Thus the prevalence rate 
from this study is 13.18% 
 
Our study similar to that by R.K.Vidyabati (2006) , shows that there 
is hypertriglyceridemia among the patients who subsequentally developed 
preeclampsia. Their study also showed that total cholesterol,LDL,VLDL 
levels were also higher in preeclampsia women which was similar to our 
study. 
 
But the mean value of HDL for both the groups were similar in their 
study. In our study the level of HDL were lower in preeclampsia group. 
 
Ray et al.(2006) showed that the mean triglyceride concentration 
were raised among preeclampsia cases than among normotensive pregnant 
women. Our study also had similar results. Does there exist a causal 
relationship? 
 
The hypothesis that answers may be that linking insulin resistance 
and triglyceridemia as risk factors for preeclampsia. 
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Carl Hubel et al(1995) in their study showed that triglycerides and 
free fatty acids are raised in preeclampsia. Malondialdehyde, a lipid 
peroxidation metabolite causes endothelial dysfunction by its interaction. 
But the interaction or effects of this metabolite is not included in our study. 
 
Ray et al(2006) showed that there exists a positive relation between 
higher BMI and increased risk of preeclampsia. In our study also the 
patients who subsequently developed preeclampsia had higher body mass 
index than the pregnant women who remained normotensive. 
 
Higher body mass index, impaired (or) abnormal glucose tolerance 
and chronic hypertension  the major features of metabolic syndrome are 
positively correlated with preeclamspsia in many studies. 
 
The study by Barden et al (1999) shows irrespective of the obstetric 
score women with preeclampsia had higher BMI during pregnancy 
compared to normotensive pregnancies. 
 
TGL levels were raised in preeclampsia women (than the normal rise 
during pregnancy ) and after six weeks of delivery the TGL levels were 
decreased ; in Barden et al study.But in our study the concentration of TGL 
post pregnancy were not included. 
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Sattar et al (1997) showed that the increased level of cholesterol and 
TGL in preeclamptic women. In our study women who developed 
preeclampsia had a higher TGL even before its development. 
 
Kaaja et al(1995) showed raised triglyceride and low HDL in 
preeclampsia women. In our study also the levels of total cholesterol, 
triglycerides , LDL,VLDL were raised in preeclamptic women. The levels 
of HDL were lower. 
 
These abnormal lipid profile lead to endothelial cell dysfunction – a 
protean step in the pathogenesis of preeclampsia. 
 
Increased F2 isoprostane was found in patients with increased LDL 
concentration , in a study by The National Heart Foundation of Australia. 
Our study did not address isoprostane F2. To establish an association 
between isoprostane F2 and preeclampsia more studies are required. 
 
Similar to theirs our study also found a low HDL concentration in 
women with preeclampsia. 
 
Bendomir studied the correlation between raised sub fraction of 
lipoprotein and new onset proteinuric hypertension in pregnancy. 
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In our study lipoprotein sub fraction were not studied. Further studies 
are required to determine the effects of lipoprotein sub fraction in 
pregnancy. 
 
Anceshchi et al (1992) found altered ratio of cholesterol to 
phospholipids in the membrane of RBC in patients with preeclampsia. The 
studies of membrane phospholipids were not included in our study. 
 
Our study similar to that by Kokia et al 1999 shows significant raised 
levels of TGL in preeclamptic women. 
 
When variables with statistical significance were put in to binary 
logistic regression model, taking development of preeclampsia as dependent 
variable, TGL was most significant. 
 
The ROC curves for total Cholestrol,HDL,VLDL,TGL,LDL for their 
role as predictors shows that  TGL has maximum area under the curve , 
revealing that TGL is the most efficient predictor among the components of 
lipid profile . 
 
Many studies shows that there exists correlation between  obesity & 
TGL levels .Increase  in BMI increases TGL levels which  in turn puts the 
patient at risk for developing preeclampsia. 
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Thus, pre pregnant weight reduction and life style modification may 
help in reducing the occurrence of preeclampsia. 
 
Further studies are necessary to establish the role of pre pregnant 
weight reduction and to find out the whether this would help in reducing the 
incidence of preeclampsia. 
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CONCLUSION 
 
After analysing and comparing the results between the preeclampsia cohort 
and normal cohort it was concluded that  
• The pre-pregnant BMI was higher among the patients who developed 
preeclampsia than normotensive counterparts. 
• The study cohort had a higher Total cholesterol, Triglyceride, Low 
density Lipoprotein, Very Low Density Lipoprotein levels. 
• The preeclampsia cohort also had a lower HDL level. 
• Thus there exists a positive correlation between dyslipidemia and 
development of preeclampsia.  
• Therefore abnormal lipid profile before 20 weeks is a very good 
predictor of preeclampsia development. 
 
Thus it may be concluded that, detecting dyslipidemia before 20 
weeks of gestation would help us to recognise pregnancies at high risk for 
preeclampsia  even before the clinical syndrome. 
 
Early recognition ,would help us in offering better surveillance to 
detect and treat the disease earlier for a better maternal and perinatal 
outcome. 
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Given that the raised triglyceridemia as a feature of the insulin 
resistance syndrome; interventional studies are required to find out whether 
pre-pregnancy weight reduction can lower the risk of preeclampsia. 
 
The determination of insulin levels, inflammatory markers in early 
pregnancy and then followed by a thorough assessment of the outcome 
through a large cohort study, may help in addressing the role of metabolic 
syndrome in causation of preeclampsia. 
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KEY  TO  MASTER  CHART 
 
S.No    - Serial Number 
SEC    - Socio Economic Status 
Prev H/O pre eclampsia - Pre eclampsia in past pregnancy 
BMI    - Body Mass Index 
TC    - Total Cholesterol 
HDL    - High Density Lipoproteins 
LDL    - Low Density Lipoproteins 
VLDL   - Very Low Density Lipoproteins 
TGL    - Triglycerides 
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PROFORMA 
 
S.no 
Name 
Age 
Obstetric Score 
Booking Status 
Socio Economic Status 
LMP 
EDD 
Menstrual History 
Obstetric History 
H/o preeclampsia in Previous Pregnancy 
Family History 
Any H/o DM/HT/ Bronchial Asthma / Cardiac / Thyriod Disease/Renal 
disease. 
Pre-pregnant weight 
 
General Examination 
Height  Weight     
Anaemia  Jaundice  Pedal edema JVP 
Vitals 
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PR:   BP:   RR: 
Systemic examination : 
Respiratory System. 
Cardiovascular System. 
CNS : 
Obstetric Examination 
 
Investigation : 
Albumin 
 Urine          Sugar 
Deposits 
VDRL 
NVP 
Blood grouping & typing 
CBC  
Blood sugar 
Sr . Creatinine 
Serum Lipid Profile 
Obstetric Ultrasound. 
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1 Selvi 30 primi 11/5/2010 8/12/2011 4 - 152 68 29.43213296 298 46.2 392.9 173.56 78.44 yes 
2 Solaiyammal 26 primi 10/21/2010 7/28/2011 4 - 143 62 30.31933102 278 56 386.2 144.26 77.24 yes 
3 sivagami 17 primi 10/20/2010 7/27/2011 4 - 159 76 30.06210197 208 46 303.2 101.4 60.64 yes 
4 Esther 21 primi 11/15/2010 8/22/2011 3 - 148 68 31.04455807 211 46.2 314.6 101.88 62.92 yes 
5 bindu 28 G2P1L0 11/23/2010 8/30/2011 5 yes 152 65 28.13365651 201 46.2 302.7 94.26 60.54 yes 
6 keerthana 23 G2P1L1 11/9/2010 8/16/2011 5 no 145 65 30.91557669 259 47.6 393.9 132.62 78.78 yes 
7 valliyammal 21 primi 11/1/2010 8/8/2011 4 - 141 65 32.69453247 302 46 292 197.82 58.4 yes 
8 suryakumari 24 G2P1L1 11/7/2010 8/14/2011 5 no 148 52 23.73995617 288 52 386 158 77.2 yes 
9 latha 28 G2P1L1 11/14/2010 8/21/2011 4 NO 148 69 31.50109569 276 45.6 394.8 151 78.96 yes 
10 nadiya 27 G2P1L1 11/9/2010 8/16/2011 4 no 150 55 24.44444444 202 44.3 299.2 97.85 59.84 yes 
11 lakshmi 21 primi 12/7/2010 9/13/2011 4 - 148 55 25.10956903 240 48.1 276.9 138.2 55.38 yes 
12 gracy 22 G2P1L1 12/21/2010 9/27/2011 5 yes 160 62 24.21875 278 45.6 395.6 154.12 79.12 yes 
13 sarala 19 primi 11/30/2010 9/6/2011 5 No 140 45 22.95918367 165 52 92 94.6 18.4 yes 
14 samundeeshwari 27 G2P1L1 12/5/2010 9/11/2011 4 yes 149 44 19.81892708 202 39 172 128.6 34.4 yes 
15 kanimozhi 25 primi 11/23/2010 8/30/2011 4 No 155 59 24.55775234 202 56 300.3 85.94 60.06 yes 
16 reshmi 26 primi 11/15/2010 8/22/2011 4 No 155 68 28.30385016 298 42.5 302.8 194.94 60.56 yes 
17 swapna 21 primi 11/12/2010 8/19/2011 5 No 158 68 27.23922448 312 48 298 204.4 59.6 yes 
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1 Sarasvathy 26 G2P1L1 10/21/2010 7/28/2011 4 yes 143 48 24 140 45 88 77.4 17.6 No 
2 Kumudha 28 primi 10/30/2010 8/6/2011 3 - 152 56 25 160 49 93 92.5 18.6 No 
3 gayathri 28 primi 10/29/2010 8/5/2011 5 - 147 52 24.06404739 175 52 101 105.8 20.5 No 
4 sumathi 28 G2P1L1 10/20/2010 7/27/2011 5 - 143 62 30.31933102 136 55 137 53.9 27.4 No 
5 Chithra 27 G2P1L1 10/8/2010 7/15/2011 5 No 141 40 20.11971229 152 40 80 94.4 17.6 No 
6 venda 21 G2P1L1 10/13/2010 7/20/2011 5 No 147 43 19.89911611 155 34 80 105 16 No 
7 Mafagadham 32 G3P2L2 11/4/2010 8/11/2011 5 No 151 42 18.42024473 148 43 130 79 26 No 
8 sakunthala 30 G2P1L1 11/2/2010 8/9/2011 4 No 149 54 24.32322868 163 37 142 95.6 28.4 No 
9 jayanthi 22 primi 10/14/2010 7/21/2011 5 - 145 52 24.73246136 158 50 189 100.2 37.8 No 
10 mahesh 25 primi 10/24/2010 7/31/2011 3 - 159 55 21.75546853 201 53 148 118.4 29.6 No 
11 priya 24 G2P1L1 11/4/2010 8/11/2011 3 - 144 56 27.00617284 136 55 136 53.8 27.2 No 
12 karthiga 22 G2P1L1 10/24/2010 7/31/2011 5 no 140 44 22.44897959 146 44 148 72.4 29.6 No 
13 ammu 30 G2P1L1 11/12/2010 8/19/2011 4 no 144 49 23.63040123 147 49 168 64.4 33.6 No 
14 brinda 26 primi 11/6/2010 8/13/2011 5 - 152 58 25.10387812 198 49 203 108.4 40.6 No 
15 Devi 27 G2P1L1 10/30/2010 8/6/2011 5 NO 147 50 23.1385071 166 42 158 84.4 31.6 No 
16 Poornima 25 primi 10/20/2010 7/27/2011 4 - 151 47 20.613131 185 52 179 97.2 35.8 No 
17 nagajothi 22 primi 11/1/2010 8/8/2011 4 - 153 48 20.504934 167 46 94 102 18.8 No 
18 chithra 23 primi 11/2/2010 8/9/2011 4 - 141 46 23.13766913 171 50 185 84 37 No 
19 darshni 24 G2P1L1 11/5/2010 8/12/2011 3 No 149 44 19.81892708 168 46 185 85 37 No 
20 deepa 25 primi 10/27/2010 8/3/2011 5 - 157 62 25.15315023 156 46 192 71.6 38.4 No 
21 durga 22 G2P1L1 11/4/2010 8/11/2011 5 no 153 58 24.77679525 203 48 240 107 48 No 
22 pavithra 26 primi 11/16/2010 8/23/2011 3 - 148 53 24.19649379 168 46 188 84 37.6 No 
23 komala 27 primi 11/5/2010 8/12/2011 4 - 142 47 23.30886729 206 50 195 117 39 No 
24 thilaga 23 primi 11/20/2010 8/27/2011 4 - 158 54 21.63114885 184 76 183 71.4 36.6 No 
25 nandini 25 G2P1L1 11/27/2010 9/3/2011 4 - 146 51 23.92568962 202 52 200 110 40 No 
26 shobana 21 primi 11/24/2010 8/31/2011 5 - 154 50 21.08281329 192 52 165 107 33 No 
27 JOTHI 25 primi 11/9/2010 8/16/2011 4 - 158 54 21.63114885 198 50 162 115 32.4 No 
28 suganthi 26 primi 11/1/2010 8/8/2011 5 - 140 45 22.95918367 196 48 194 106 38.8 No 
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29 lavanya 25 G2P1L1 11/18/2010 8/25/2011 4 No 147 43 19.89911611 163 38 142 96.6 28.4 No 
30 prabavathy 23 primi 11/13/2010 8/20/2011 5 - 149 54 24.32322868 198 52 154 115.2 30.8 No 
31 meena 25 primi 11/6/2010 8/13/2011 5 - 154 50 21.08281329 178 46 169 98.2 33.8 No 
32 jenifer 24 G2P1L1 11/25/2010 9/1/2011 4 no 149 54 24.32322868 203 52.3 206 129.56 41.2 No 
33 ramajyothi 22 G2P1L1 12/1/2010 9/7/2011 4 no 157 54 21.90758246 200 50.8 152.4 119.2 30.48 No 
34 deepa 19 primi 11/18/2010 8/25/2011 4 - 160 55 21.484375 239 62.9 387.6 139.2 77.52 No 
35 philomeena 30 G2P1L1 12/4/2010 9/10/2011 3 No 153 58 24.77679525 221 75.3 222.2 101.76 44.44 No 
36 mahalaksmi 22 primi 12/8/2010 9/14/2011 4 - 145 48 22.82996433 204 48.1 191.9 118 38.38 No 
37 kala 26 G2P1L1 11/19/2010 8/26/2011 5 NO 152 48 20.77562327 181 80.3 181 64.7 36.2 No 
38 RAMADEVI 25 primi 11/26/2010 9/2/2011 4 - 159 54 21.35991456 240 65.1 137.1 144.88 27.42 No 
39 sharmila 20 primi 12/4/2010 9/10/2011 4 - 149 49 22.07107788 205 66.5 103.9 118.22 20.78 No 
40 devi 30 G3P2L2 12/5/2010 9/11/2011 3 no 159 54 21.35991456 284 63.8 165.4 188.2 33.08 No 
41 gomathi 33 G3P2L2 11/30/2010 9/6/2011 4 no 156 51 20.9566075 193 60.5 156.8 101 31.36 No 
42 jansirani 28 G2P1L1 12/4/2010 9/10/2011 4 no 142 47 23.30886729 231 78.4 297.1 93.65 59.42 No 
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43 backialakshmi 32 primi 11/19/2010 8/26/2011 5 - 149 54 24.32322868 237 49.5 159.3 55.84 31.86 No 
44 gomathi 28 primi 11/27/2010 9/3/2011 3 - 146 51 23.92568962 155 75.8 85.5 62.8 17.1 No 
45 sabitha 22 primi 11/20/2010 8/27/2011 3 - 141 46 23.13766913 140 52.4 132.9 61.92 26.58 No 
46 pushpa 22 G2P1L1 12/10/2010 9/16/2011 4 no 154 50 21.08281329 172 49.9 185.2 85.76 37.04 No 
47 muthulakshmi  30 G3P2L2 11/25/2010 9/1/2011 4 No 152 47 20.34279778 145 46 92 80.6 18.4 No 
48 sasikala 22 G2P1L1 11/21/2010 8/28/2011 4 yes 157 52 21.09619051 202 55 200 107 40 No 
49 nirmala 18 primi 12/9/2010 9/15/2011 5 No 148 53 24.19649379 175 43 101 111.8 20.2 No 
50 rukmani 22 primi 11/20/2010 8/27/2011 3 No 141 46 23.13766913 142 52 132 63.6 26.4 No 
51 sarojini 30 primi 12/11/2011 9/16/2012 4 No 147 42 19.43634597 156 42 85 97 17 No 
52 pushpa 22 primi 11/18/2010 8/25/2011 3 No 151 56 24.5603263 168 46 172 87.6 34.4 No 
53 kasiyammal 22 primi 11/21/2010 8/28/2011 4 No 149 54 24.32322868 156 34 72 107.6 14.4 No 
54 suseela 32 G2P1L1 12/15/2010 9/21/2011 4 No 159 54 21.35991456 143 46 126 71.8 25.2 No 
55 mariyammal 38 G2P1L1 12/9/2011 9/14/2012 5 yes 152 57 24.67105263 166 39 146.5 97.7 29.3 No 
56 karpagam 27 primi 11/26/2010 9/2/2011 4 No 143 48 23.47303047 188 45.9 183 105.5 36.6 No 
57 shankari 22 primi 11/19/2010 8/26/2011 3 No 154 59 24.87771968 198 55 142.5 144.5 28.5 No 
58 sudha 27 primi 11/30/2010 9/6/2011 5 No 140 45 22.95918367 201 56 208.6 103.2 41.72 No 
59 pramila 23 G3P2L2 11/27/2010 9/3/2011 4 No 160 55 21.484375 147 48 99.8 79.03 19.96 No 
60 manimala 25 G2P1L1 12/8/2010 9/14/2011 4 No 153 48 20.504934 145 58 88.2 69.36 17.64 No 
61 bishnu 30 G2P1L1 12/15/2010 9/21/2011 4 No 146 51 23.92568962 196 52 202.3 103.5 40.46 No 
62 SELVI 22 primi 12/22/2010 9/28/2011 5 No 142 47 23.30886729 165 48 136 89.8 27.2 No 
63 BHUVANA 22 primi 12/10/2010 9/16/2011 5 No 152 57 24.67105263 188 54 184 97.2 36.8 No 
64 MANJU 27 primi 11/27/2010 9/3/2011 4 No 148 43 19.6311176 164 48 92 97.6 18.4 No 
65 MARAGADHAM 26 primi 12/19/2010 9/25/2011 3 No 153 58 24.77679525 143 56 82.6 70.48 16.52 No 
66 SHAKUNTHALA 27 G2P1L1 12/13/2010 9/19/2011 4 No 141 46 23.13766913 172 53 186 81.8 37.2 No 
67 SHAKILA 26 primi 11/30/2010 9/6/2011 4 No 159 54 21.35991456 165 44 172 86.6 34.4 No 
68 SHAFREEN 28 primi 11/25/2010 9/1/2011 4 No 151 56 24.5603263 152 48 176 68.8 35.2 No 
69 JANANI 21 primi 12/5/2010 9/11/2011 4 No 149 54 24.32322868 162 43 108.6 97.28 21.72 No 
70 yuvashree 28 primi 12/9/2010 9/15/2011 4 No 144 49 23.63040123 246 49 303.2 136.36 60.64 No 
71 jamrath 28 primi 12/15/2010 9/21/2011 4 No 155 50 20.81165453 182 76 182.5 68.5 36.5 No 
72 suganya 25 G2P1L1 12/7/2010 9/13/2011 3 No 157 52 21.09619051 185 65 176.3 84.74 35.26 No 
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73 indira 23 primi 12/10/2010 9/16/2011 5 no 148 43 19.6311176 203 53 182 113.6 36.4 No 
74 Kasthuri 22 G2P1L1 12/6/2010 9/12/2011 4 No 160 55 21.484375 172 48 163 91.4 32.6 No 
75 Jeyachitra 31 primi 12/30/2010 10/6/2011 5 No 151 56 24.5603263 192 51 163 108.4 32.6 No 
76 Rani 28 G2P1L1 12/7/2010 9/13/2011 4 No 156 51 20.9566075 193 48.5 178.5 108.74 35.7 No 
77 Ranjani 27 primi 12/8/2010 9/14/2011 4 No 149 44 19.81892708 186.3 52.2 106.8 109.74 21.36 No 
78 Singari 22 primi 12/20/2010 9/26/2011 4 No 158 53 21.23057202 188 39 175.6 113.8 35.12 No 
79 Nirmala 27 primi 12/12/2010 9/18/2011 4 No 143 48 23.47303047 200 51.3 146.2 119.6 29.24 No 
80 Vijayalakshmi 27 primi 12/7/2010 9/13/2011 4 No 151 56 24.5603263 236 60.8 178.9 139.4 35.78 No 
81 Gnaneshwari 29 primi 12/15/2010 9/21/2011 3 No 148 53 24.19649379 173 50 186.4 85.72 37.28 No 
82 vandana 21 primi 12/5/2010 9/11/2011 4 No 142 47 23.30886729 142 52.6 136.9 62.02 27.38 No 
83 madhangi 22 primi 12/7/2010 9/13/2011 5 No 140 45 22.95918367 154 65.1 88.7 71.16 17.74 No 
84 Akila 23 primi 12/10/2010 9/16/2011 3 No 142 47 23.30886729 134 50.2 142.6 55.28 28.52 No 
85 rajalakshmi 28 G2P1L1 12/5/2010 9/11/2011 4 No 154 59 24.87771968 193 59.6 88.7 115.6 17.74 No 
86 Sindu 25 primi 10/22/2010 7/29/2011 4 No 146 54 25.33308313 140 44 96 76.8 19.2 No 
87 amudha 24 primi 10/31/2010 8/7/2011 4 No 142 46 22.81293394 166 52 99 94.2 19.8 No 
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88 lakshminarayani 28 primi 11/4/2010 8/11/2011 5 No 156 59 24.24391847 200 59 201 100.8 40.2 No 
89 aparna 26 G2P1L1 10/27/2010 8/3/2011 5 No 154 60 25.29937595 176 55 105 100 21 No 
90 arthi 23 primi 11/3/2010 8/10/2011 4 No 158 58 23.23345618 202 54 196 108.8 39.2 No 
91 nadhiya 24 primi 11/5/2010 8/12/2011 5 No 152 53 22.93975069 136 49 136.6 59.68 27.32 No 
92 devaki 20 primi 10/23/2010 7/30/2011 5 No 158 62 24.8357635 143 43 152 69.6 30.4 No 
93 sathya 25 primi 11/17/2010 8/24/2011 5 No 160 65 25.390625 146 56 163.5 57.3 32.7 No 
94 kavitha 22 primi 11/13/2010 8/20/2011 4 No 162 65 24.76756592 132 55 202.2 36.56 40.44 No 
95 ushadevi 23 G2P1L1 10/29/2010 8/5/2011 4 No 157 59 23.93606231 162 46 185 79 37 No 
96 Mari  22 primi 11/4/2010 8/11/2011 4 No 153 53 22.64086462 176 58 186 80.8 37.2 No 
97 ganga 21 primi 10/26/2010 8/2/2011 5 no 158 62 24.8357635 154.2 48.6 132.2 79.16 26.44 No 
98 ponni 25 G2P1L1 11/9/2010 8/16/2011 4 no 156 55 22.60026298 158.6 49.6 202.6 68.48 40.52 No 
99 manimegalai 27 primi 11/14/2010 8/21/2011 4 no 157 58 23.53036634 159.6 48.6 182 74.6 36.4 No 
## roopa 28 G2P1L1 11/16/2010 8/23/2011 4 no 160 63 24.609375 184.5 49.6 172.4 100.42 34.48 No 
## Ramya 26 primi 11/19/2010 8/26/2011 4 no 158 58 23.23345618 174 65 146 79.8 29.2 No 
## nisha 21 primi 11/1/2010 8/8/2011 4 no 149 58 26.12494933 172.5 52.5 148 90.3 29.6 No 
## sangeeta 25 G2P1L1 11/8/2010 8/15/2011 4 NO 151 54 23.68317179 146.8 52.4 169.6 60.48 33.92 No 
## viji 24 primi 11/25/2010 9/1/2011 4 NO 153 56 23.922423 184 49 146 105.8 29.2 No 
## sheeli 23 primi 11/3/2010 8/10/2011 4 No 158 60 24.03460984 184.6 49.5 184 98.3 36.8 No 
## sabeena 25 primi 11/13/2010 8/20/2011 5 No 154 56 23.61275089 162 44 126.5 92.7 25.3 No 
## angelin 25 primi 12/4/2010 9/10/2011 5 No 156 62 25.47666009 180 62.5 146 88.7 29.2 No 
## thulasi 22 primi 12/8/2010 9/14/2011 4 No 152 54 23.37257618 202 65 105.6 115.88 21.12 No 
## vallikannu 24 primi 11/18/2010 8/25/2011 4 no 159 54 21.35991456 145 65.2 82.5 63.3 16.5 No 
## sakthi 28 primi 11/22/2010 8/29/2011 4 no 161 65 25.07619305 142.2 52.6 135 62.599 27 No 
## vidya 23 primi 12/12/2010 9/18/2011 5 no 148 54 24.65303141 168.6 52.6 186.4 78.72 37.28 No 
## sivakumari 25 G2P1L1 12/15/2010 9/21/2011 4 no 149 54 24.32322868 186.5 48.6 192 99.5 38.4 No 
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Ra xg;Gjy; gbtk; ; ; ;; ; ;; ; ;  
 
Ma;T nra;ag;gLk; jiyg;G   :  
kfsph; kw;Wk; kfg;NgW kUj;Jtj;Jiw : 
fPog;ghf;fk; kUj;Jtf;fy;Y}up   : 
gq;F ngWgthpd; ngaH    : 
gq;F ngUgthpd; taJ    : 
gq;F ngUgthpd; vz;    : 
gq;F ngWgtH ,jid (√) Fwpf;fTk;. 
 NkNy Fwpg;gpl;Ls;s kUj;Jt Ma;tpd; tptuq;fs; vdf;F 
tpsf;fg;gl;lJ. vd;Dila re;Njfq;fis Nfl;fTk; 
mjw;fhd jFe;j tpsf;fw;fis Nfl;f 
tha;g;gspf;fg;gl;lLs;sJ vd mwpe;J nfhz;Nld;. 
 
 ehd; ,t;tha;tpy; jd;dpr;irahfj; jhd; 
gq;Nfw;fpNwd;.ve;j fhuzj;jpdhNyh ve;j rl;lrpf;fSf;Fk; 
cl;glhky; ehd; ,t;tha;tpy; ,Ue;J tpyfpf; 
nfhs;syhk; vd;Wk; mwpe;J nfhz;Nld;.\ 
 
 ,e;j Ma;T rk;ge;jkhfNth mij rhHe;J NkYk; Ma;T 
Nkw;nfhs;Sk; NghJ ,e;j Ma;tpy; gq;F ngWk; 
kUj;JtH vd;Dila kUj;Jt mwpf;iffis ghh;g;gjw;F 
vd; mDkjp Njitapy;iy vd mwpe;J nfhs;fpNwhd;. 
 
 ,e;j Ma;tpd; %yk; fpilf;Fk; jftiyNah KbitNah 
gad;gLj;jpf; nfhs;s kWf;fkhl;Nlhd;. 
 
 ,e;j Ma;tpy; gq;F nfhs;s xg;Gf; nfhs;fpNwd;. ,e;j 
Ma;it Nkw;nfhs;Sk; kUj;Jt mzpf;F cd;ikAld; 
,Ug;Ngd; vd;Wk; cWjpaspf;fpNwd;. 
 
 ,e;j Ma;tpy; xUKiw 5 kp ,uj;j ghpNrhjidf;fhf 
vLj;jf; nfhs;sg;gLk; vd;gij mwpNtd;. 
 
gq;Nfw;gthpd; ifnahg;gk;____________ 
,lk;_________________         Njjp__________________  
 
gq;Nfw;gtupd; ngaH kw;Wk; tpyhrk;  
rhl;rpahshpd; ifnahg;gk; 
 
,lk;_____________ Njjp___________________  
rhl;rpahshpd; ngaH kw;Wk; tpyhrk; 
  
Ma;thshpd; ifnahg;gk; 
,lk;_____________ Njjp____________________ 
Ma;thshpd; ngaH__________________________   
 
